Supplrmentary Figures S1-S4 and Tables S1-S5 from Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome

Supplementary Fig. S1: Percentage of drugs per drug class among drug libraries used in the HTS; Supplementary Fig. S2: Synergistic GFP reactivation in YB5 cells by HDACi TSA and positive hits identified in the HTS; Supplementary Fig. S3: Optimization of the treatment schedule of the decitabine and proscillaridin A combination; Supplementary Fig. S4: Transcriptome analysis using Metascape; Supplementary Table S1: List of GO-Terms identified by Metascape analysis in gene data sets exclusively up-regulated by proscillaridin A treatment and exclusively up-regulated by the combination treatment; Supplementary Table S2: List of GO-Terms identified by Metascape analysis among down-regulated genes shared by proscillaridin A and the combinatorial treatment with decitabine; Supplementary Table S3: Antagonistic hits identified in combination HTS with sequential decitabine treatment; Supplementary Table S4. Antagonistic hits identified in combination HTS with simultaneous decitabine treatment; Supplementary Table S5. Antagonistic hits identified in combination HTS with sequential TSA treatment.